Therapeutic Use of Immunoglobulins

Advances in Pediatrics

Volumn 57, Issue 1, 2010, Pages 185-218

  Stiehm, E Richard ^a   Orange, Jordan S ^b   Ballow, Mark ^c   Lehman, Heather ^c  

^a MATTEL CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

CHILD; COMMUNICABLE DISEASE; DRUG EFFECT; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; MALE; PRESCHOOL CHILD; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASES; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOMODULATION; MALE; QUALITY CONTROL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 78149399463     PISSN: 00653101     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yapd.2010.08.005     Document Type: Review

References (171)

1. Lucey D. Anthrax. Principles and practice of infectious diseases 2005, 3618-3624. Elsevier/Churchill Livingston, Philadelphia, 2485-91. 6th edition. G. Mandel, J.E. Bennett, R. Donin (Eds.).
2. Gold H., Chester P.A. Studies on anthrax: clinical report of ten human cases. J Lab Clin Med 1935, 21:134-152.
3. Cidrap H.H.S. to buy 20,000 courses of anthrax antitoxin Available at:, Accessed June 20, 2006. http://cidrap.umn.edu/cidrap/content/bt/anthrax/news/jun2006anthrax.html.
4. Migone T., Subramanian M., Zhong J., et al. Raxibacumab or the treatment of inhalational anthrax. N Engl J Med 2009, 361:135-144.
5. Stiehm E.R., Keller M.A. Passive immunization. Textbook of pediatric infectious diseases 2009, 3447-3479. Saunders/Elsevier, Philadelphia. 6th edition. R.D. Feigen, J.D. Cherry, G.J. Demmler-Harrison (Eds.).
6. Diphtheria. Red Book: 2009 Report of the Committee on infectious diseases 2009, 280-283. American Academy of Pediatrics, American Academy of Pediatrics, Elk Grove Village (IL). 28th edition. L.K. Pickering, C.J. Baker, D.W. Kimberlin (Eds.).
7. Faber H.K., McIntosh R. History of the American Pediatric Society 1887-1965 1966, McGraw-Hill, New York, p. 35-6.
8. Tetanus. Red Book: 2009 Report of the Committee on infectious diseases 2009, 655-660. American Academy of Pediatrics, American Academy of Pediatrics, Elk Grove Village (IL). 28th edition. L.K. Pickering, C.J. Baker, D.W. Kimberlin (Eds.).
9. Lee D.C., Lederman H.M. Anti-tetanus toxoid antibodies in intravenous gamma globulin: an alternative to tetanus immune globulin. J Infect Dis 1992, 166:642-645.
10. Wilcox M.H. Treatment of Clostridium difficile infection. J Antimicrob Chemother 1998, 41(Suppl C):41-46.
11. Cleary R. Clostridium difficile-associated diarrhea and colitis: clinical manifestations, diagnosis, and treatment. Dis Colon Rectum 1998, 41:1435-1449.
12. Kyne L., Warny M., Qamar A., et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin. N Engl J Med 2000, 342:390-397.
13. McPherson S., Rees C.J., Ellis R., et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006, 49:640-645.
14. Leung D., Kelly Y.M., Boguniewicz C.P., et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991, 118:633-637.
15. Salcedo J., Keates S., Pothoulakis C., et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gastroenterology 1997, 41:366-370.
16. Arnon S.S., Schechter R., Inglesby T.V., et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1071.
17. Berg B.O. Syndrome of infant botulism. Pediatrics 1977, 59:321-322.
18. Botulism in the United States, 1899-1977. Handbook for epidemiologists, clinicians and laboratory workers 1979, Centers for Disease Control, Centers for Disease Control, Atlanta (GA).
19. Chertow D.S., Tan E.T., Maslanka S.E., et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006, 2476-2479.
20. Souayah N., Karim H., Kamin S.S., et al. Severe botulism after focal injection of botulinum toxin. Neurology 2006, 67:1855-1856.
21. Centers for Disease Control and Prevention (CDC) Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Report 2010, 59(10):299.
22. Botulism and infant botulism. Red Book: 2009 Report of the Committee on infectious diseases 2009, 259-262. American Academy of Pediatrics, American Academy of Pediatrics, Elk Grove Village (IL). 28th edition. L.K. Pickering, C.J. Baker, D.W. Kimberlin (Eds.).
23. Arnon S.S., Schechter R., Maslanka S.E., et al. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006, 345:462-471.
24. Alexander H.E. Treatment of Haemophilus influenzae infection and of meningococcic and pneumococcic meningitis. Am J Dis Child 1943, 66:172-187.
25. Casadevall A., Scharff M.D. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995, 21:150-161.
26. Simoes E.A.F., Groothuis J.R., Tristram D.A., et al. Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children. J Pediatr 1996, 129:214-219.
27. 9/L or more: effect on viral, opportunistic, and bacterial infections. JAMA 1992, 268:483-488.
28. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991, 325:73-80. National Institute of Child Health and Human Development (NICHHD) Intravenous Immunoglobulin Study Group.
29. Casadevall A. Passive antibody therapies: progress and continuing challenges. Clin Immunol 1999, 93:5-15.
30. Lucchesi P.F., Bowman J.E. Antitoxin versus no antitoxin in scarlet fever. JAMA 1930, 103:1049-1051.
31. Perez C.M., Kubak B.M., Cryer H.G., et al. Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review. Am J Med 1997, 102:111-113.
32. Schrage B., Duan G., Yang L.P., et al. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis 2006, 43:743-746.
33. Lamothe F., D'Amico P., Ghosen P., et al. Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: case report and review. Clin Infect Dis 1995, 21:1469-1470.
34. Kaul R., McGeer A., Norrby-Tegllund A., et al. Intravenous immunoglobulin for streptococcal toxic shock syndrome-a comparative observational study. Clin Infect Dis 1999, 28:800-807.
35. Staphylococcal infections. Red Book: 2009 Report of the Committee on infectious diseases 2009, 601-615. American Academy of Pediatrics, American Academy of Pediatrics, Elk Grove Village (IL). 28th edition. L.K. Pickering, C.J. Baker, D.W. Kimberlin (Eds.).
36. Melish M.E., Murata S., Fukunaga C., et al. Vaginal tampon model for toxic shock syndrome. Rev Infect Dis 1989, 11(Suppl 1):219-228. 238-46.
37. Suen J., Chesney P.J., Davis J.P. Toxic shock syndrome. Textbook of pediatric infectious diseases 2009, 862-884. Saunders/Elsevier, Philadelphia. 6th edition. R.D. Feigen, J.D. Cherry, G.J. Demmler-Harrison (Eds.).
38. Fischer G.W., Cieslak T.J., Wilson S.R., et al. Opsonic antibodies to Staphylococcus epidermidis: in vitro and in vivo studies using human intravenous immune globulin. J Infect Dis 1994, 169:324-329.
39. Jenson H.B., Pollock B.H. The role of intravenous immunoglobulin for the prevention and treatment of neonatal sepsis. Semin Perinatol 1998, 22:50-63.
40. Baker C.J., Melish M.E., Hall R.T. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. N Engl J Med 1992, 327:213-219.
41. Waisbren B.A. The treatment of bacterial infections with the combination of antibiotics and gamma globulin. Antibiot Chemother 1957, 7:322-332.
42. Kelly J. Immunotherapy against antibiotic-resistant bacteria: the Russian experience with an antistaphyloccocal hyperimmune plasma and immunoglobulin. Microbes Infect 2000, 2:1383-1392.
43. Fisher M.W. Synergism between human gamma globulin and chloramphenicol in the treatment of experimental bacterial infections. Antibiot Chemother 1956, 7:315-321.
44. Lewis D.B., Tu W. The physiologic immunodeficiency of immaturity. Immunologic disorders in infants and children 2004, 687-760. Elsevier/Saunders, Philadelphia. 5th edition. E.R. Stiehm, H.D. Ochs, J.W. Winkelstein (Eds.).
45. Jenson H.B., Pollock B.H. Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis. Pediatrics 1997, 99:E2.
46. Lacy J.B., Ohlsson A. Administration of intravenous immunoglobulins for prophylaxis or treatment of infection in preterm infants: meta-analysis. Arch Dis Child 1995, 72:F151-F155.
47. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low birth-weight infants (Cochrane Review). The Cochrane Library. Oxford. Issue 1. 2001.
48. Ohlsson A., Lacy J.B. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev 2004, (1). CD001239.
49. Benjamin D.K., Schelonka R., White R., et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol 2006, 26:290-295.
50. Bloom B., Schelonka R., Kueser T., et al. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J 2005, 24:858-866.
51. NIH Consensus Development Conference: diseases, doses, recommendations for intravenous immunoglobulin. HLB Newsletter. Natl Inst Heart Lung Blood Dis 1990, 6:73-78.
52. Glinz P.W., Nydegger U.E., Ricklin T., et al. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. Intensive Care Med 1985, 11:288-294.
53. Sandberg E.T., Kline M.W., Shearer W.T. The secondary immunodeficiencies. Immunologic disorders in infants and children 1996, 553-601. WB Saunders, Philadelphia. 4th edition. E.R. Stiehm (Ed.).
54. Laupland K.B., Kirkpatrick A.W., Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007, 35:2686-2692.
55. Kempe C.H. Studies on smallpox and complications of smallpox vaccination. Pediatrics 1960, 26:176-189.
56. Smallpox (variola). Red Book: 2009 Report of the Committee on infectious diseases 2009, 596-598. American Academy of Pediatrics, American Academy of Pediatrics, Elk Grove Village (IL). 28th edition. L.K. Pickering, C.J. Baker, D.W. Kimberlin (Eds.).
57. Brown K.E. Parvovirus B19. Mandell, Douglas and Bennett's principles and practice of infectious diseases 2000, 1685-1693. Churchill Livingstone, Philadelphia. 5th edition. G.L. Mandell, J.E. Bennett, R. Doling (Eds.).
58. Inoue S., Kinra N.K., Mukkamala S.R., et al. Parvovirus B19 infection: aplastic crisis, erythema infectiosum and idiopathic thrombocytopenic purpura. Pediatr Infect Dis J 1991, 10:251-253.
59. Young N.S. Parvovirus infection and its treatment. Clin Exp Immunol 1996, 104(Suppl 1):26-30.
60. Parvovirus B19. Red Book: 2009 Report of the Committee on infectious diseases 2009, 491-494. American Academy of Pediatrics, American Academy of Pediatrics, Elk Grove Village (IL). 28th edition. L.K. Pickering, C.J. Baker, D.W. Kimberlin (Eds.).
61. McGhee S.A., Kaska B., Liebhaber M., et al. Persistent parvovirus-associated chronic fatigue treated with high dose intravenous immunoglobulin. Pediatr Infect Dis J 2005, 24:272-274.
62. Frickhofen N.J., Abkowitz L., Safford M., et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia with AIDS. Ann Intern Med 1990, 113:926-933.
63. Koduri P.R., Kumapley R.J., Valladares J., et al. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin: a report of eight patients. Am J Hematol 1999, 61:16-20.
64. Bulinski P., Toledo-Pereyra L.H., Dalal S., et al. Cytomegalovirus infection in kidney transplantation: prophylaxis and management. Transplant Proc 1996, 28:3310-3311.
65. Jassal S.V., Roscoe J.M., Zaltzman J.S., et al. Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 1998, 9:1697-1708.
66. Bonaros N.E., Kocher A., Dunkler D., et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation 2004, 77:890-897.
67. Paar D.P., Pollard R.B. Immunotherapy of CMV infections. Adv Exp Med Biol 1996, 394:145-151.
68. Negishi H., Yamada H., Hirayama E., et al. Intraperitoneal administration of cytomegalovirus hyperimmunoglobulin to the cytomegalovirus-infected fetus. J Perinatol 1998, 18:466-469.
69. Nigro G., Adler S.P., La Torre R., et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005, 353:1350-1362.
70. Herpes simplex. Red Book: 2009 Report of the Committee on infectious diseases 2009, 363-373. American Academy of Pediatrics, American Academy of Pediatrics, Elk Grove Village (IL). 28th edition. L.K. Pickering, C.J. Baker, D.W. Kimberlin (Eds.).
71. Masci S., De Simone C., Famularo G., et al. Intravenous immunoglobulins suppress the recurrences of genital herpes simplex virus: a clinical and immunological study. Immunopharmacol Immunotoxicol 1995, 17:33-47.
72. Delone P.J., Corkill J., Jordan M., et al. Successful treatment of Epstein-Barr virus infection with ganciclovir and cytomegalovirus hyperimmune globulin following kidney transplantation. Transplant Proc 1995, 27(Suppl 1):58-59.
73. Oettle H., Wilborn F., Schmidt C.A., et al. Treatment with ganciclovir and Ig for acute Epstein-Barr virus infection after allogeneic bone marrow transplantation. Blood 1993, 82:2257-2262.
74. Taguchi Y., Purtilo D.T., Okano M. The effect of intravenous immunoglobulin and interferon-alpha on Epstein-Barr virus-induced lymphoproliferative disorder in a liver transplant recipient. Transplantation 1994, 57:1813-1815.
75. Filipovich A.H., Gross T., Jyonouchi H., et al. Immune-mediated hematologic and oncologic disorders, including Epstein-Barr virus infection. Immunologic disorders in infants and children 1996, 855-888. WB Saunders, Philadelphia. 4th edition. E.R. Stiehm (Ed.).
76. Brunell P.A., Gershon A.A. Passive immunization against varicella zoster infections. J Infect Dis 1973, 127:415-423.
77. Varicella-zoster infections. Red Book: 2009 Report of the Committee on infectious diseases 2009, 714-727. American Academy of Pediatrics, American Academy of Pediatrics, Elk Grove Village (IL). 28th edition. L.K. Pickering, C.J. Baker, D.W. Kimberlin (Eds.).
78. Bodian D. Experimental studies on passive immunization against poliomyelitis: I. Protection with human gamma globulin against intramuscular inoculation and combined passive and active immunization. Am J Hyg 1951, 54:132-143.
79. McKinney R.E., Katz S.L., Wilfert C.M. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis 1987, 9:334-356.
80. Dwyer J.M., Erlendsson K. Intraventricular gamma-globulin for the management of enterovirus encephalitis. Pediatr Infect Dis J 1988, 7:S30-S33.
81. Kondoh H.K., Kobayashi Y., Sugio K., et al. Successful treatment of echovirus meningoencephalitis in sex-linked agammaglobulinaemia by intrathecal and intravenous injection of high titer gammaglobulin. Eur J Pediatr 1987, 146:610-612.
82. Misbah S.A., Spickett G.P., Ryba C.J., et al. Chronic enteroviral meningoencephalitis, in agammaglobulinemia: case report and literature review. J Clin Immunol 1992, 12:266-270.
83. Desmond R.A., Accortt N.A., Talley L., et al. Enteroviral meningitis: natural history and outcome of pleconaril therapy. Antimicrob Agents Chemother 2006, 50:2409-2414.
84. Abzug M.J., Keyserling H.L., Lee M.L., et al. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis 1995, 20:1201-1206.
85. Rentz A.C., Libbey J.E., Fujinami R.S., et al. Investigation of treatment failure in neonatal echovirus 7 infection. Pediatr Infect Dis 2006, 25:259-262.
86. Nagington J., Gandy G., Walker J., et al. Use of normal immunoglobulin in an echovirus 11 outbreak in a special-care baby unit. Lancet 1983, ii:443-446.
87. Terrault N.A., Zhou S., Combs C., et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996, 24:1327-1333.
88. Grazi G.L., Mazziotti A., Sama C., et al. Liver transplantation in HBsAg-positive HBV-DNA-negative cirrhotics: immunoprophylaxis and long term outcome. Liver Transpl Surg 1996, 2:418-425.
89. Samuel D., Bismuth A., Serres C., et al. HBV-infection in liver transplantation in HBsAg positive patients: experience with long-term immunoprophylaxis. Transplant Proc 1991, 23:1492-1494.
90. Makhoul B., Braun E., Herskovitz M., et al. Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis. Isr Med Assoc J 2009, 11:151-153.
91. Ben-Nathan D, Gershoni-Yahalom O, Samina I, et al. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection Available at:. http://www.biomedcentral.com/1471-2334/9/18.
92. Kudoyarova-Zubavichene N.M., Sergeyev N.N., Chepurnov A.A., et al. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis 1999, 179(Suppl 1):218-223.
93. Jahrling P.B., Geisbert T.W., Geisbert J.B., et al. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J Infect Dis 1999, 179(Suppl):224-234.
94. Mupapa K., Massamba M., Kibadi K., et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999, 179(Suppl 1):S18-S23.
95. Dumpis U., Crook D., Oksi J. Tick-borne encephalitis. Clin Infect Dis 1999, 28:882-890.
96. Von Hedenström M., Heberle U., Theobald K. Vaccination against tick-borne encephalitis (TBE): influence of simultaneous application of TBE immunoglobulin on seroconversion and rate of adverse events. Vaccine 1995, 13:759-762.
97. Maiztegui J.I., Fernandez N.J., De Damilano A.J. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979, ii:1216-1217.
98. Stockman L.J., Bellamy R., Garner P. SARS: systematic review of treatment effects. PLoS Med 2006, 3:e343. 10.1371/journal pmed0030343.
99. Orange J.S., Hossny E.M., Weiler C.R., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006, 117:S525-S553.
100. Constantine M.M., Thomas W., Whitman L., et al. Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group. Transfusion 2007, 47:2072-2080.
101. Provan D., Chapel H.M., Sewell W.A., et al. Prescribing intravenous immunoglobulin: summary of Department of Health guidelines. BMJ 2008, 337:a1831.
102. Bruton O.C. Agammaglobulinemia. Pediatrics 1952, 9:722-728.
103. Geha R.S., Notarangelo L.D., Casanova J.L., et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007, 120:776-794.
104. Boyle J.M., Buckley R.H. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol 2007, 27:497-502.
105. Leiva L.E., Zelazco M., Oleastro M., et al. Primary immunodeficiency diseases in Latin America: the second report of the LAGID registry. J Clin Immunol 2007, 27:101-108.
106. Kirkpatrick P., Riminton S. Primary immunodeficiency diseases in Australia and New Zealand. J Clin Immunol 2007, 27:517-524.
107. Luzi G., Businco L., Aiuti F. Primary immunodeficiency syndromes in Italy: a report of the national register in children and adults. J Clin Immunol 1983, 3:316-320.
108. Stray-Pedersen A., Abrahamsen T.G., Froland S.S. Primary immunodeficiency diseases in Norway. J Clin Immunol 2000, 20:477-485.
109. Conley M.E., Dobbs A.K., Farmer D.M., et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol 2009, 27:199-227.
110. Notarangelo L.D., Lanzi G., Peron S., et al. Defects of class-switch recombination. J Allergy Clin Immunol 2006, 117:855-864.
111. Yong P.F., Tarzi M., Chua I., et al. Common variable immunodeficiency: an update on etiology and management. Immunol Allergy Clin North Am 2008, 28:367-386.
112. Bonilla F.A., Bernstein I.L., Khan D.A., et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005, 94:S1-63.
113. Wolpert J., Knutsen A. Natural history of selective antibody deficiency to bacterial polysaccharide antigens in children. Pediatr Asthma Allergy Immunol 1998, 12:183-191.
114. Hanson E.P., Monaco-Shawver L., Solt L.A., et al. Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J Allergy Clin Immunol 2008, 122:1169-1177.
115. Orange J.S., Levy O., Brodeur S.R., et al. Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia. J Allergy Clin Immunol 2004, 114:650-656.
116. Orange J.S., Geha R.S., Bonilla F.A. Acute chylothorax in children: selective retention of memory T cells and natural killer cells. J Pediatr 2003, 143:243-249.
117. Strober W., Wochner R.D., Carbone P.P., et al. Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection. J Clin Invest 1967, 46:1643-1656.
118. Dalal I., Reid B., Nisbet-Brown E., et al. The outcome of patients with hypogammaglobulinemia in infancy and early childhood. J Pediatr 1998, 133:144-146.
119. Dorsey M.J., Orange J.S. Impaired specific antibody response and increased B-cell population in transient hypogammaglobulinemia of infancy. Ann Allergy Asthma Immunol 2006, 97:590-595.
120. Whelan M.A., Hwan W.H., Beausoleil J., et al. Infants presenting with recurrent infections and low immunoglobulins: characteristics and analysis of normalization. J Clin Immunol 2006, 26:7-11.
121. Yong P.F., Chee R., Grimbacher B. Hypogammaglobulinaemia. Immunol Allergy Clin North Am 2008, 28:691-713.
122. Barlan I.B., Geha R.S., Schneider L.C. Therapy for patients with recurrent infections and low serum IgG3 levels. J Allergy Clin Immunol 1993, 92:353-355.
123. Abdou N.I., Greenwell C.A., Mehta R., et al. Efficacy of intravenous gammaglobulin for immunoglobulin G subclass and/or antibody deficiency in adults. Int Arch Allergy Immunol 2009, 149:267-274.
124. Janeway C.A., Rosen F.S. The gamma globulins. IV. Therapeutic uses of gamma globulin. N Engl J Med 1966, 275:826-831.
125. Cunningham-Rundles C., Siegal F.P., Smithwick E.M., et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 1984, 101:435-439.
126. Quartier P., Debre M., De Blic J., et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr 1999, 134:589-596.
127. Pickett D., Modell V., Leighton I., et al. Impact of a physician education and patient awareness campaign on the diagnosis and management of primary immunodeficiencies. Immunol Res 2008, 40:93-94.
128. Simoens S. Pharmacoeconomics of immunoglobulins in primary immunodeficiency. Expert Rev Pharmacoecon Outcomes Res 2009, 9:375-386.
129. Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007, 2:9-18.
130. Quinti I., Pierdominici M., Marziali M., et al. European surveillance of immunoglobulin safety-results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries. Clin Immunol 2002, 104:231-236.
131. Gelfand E.W. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006, 6:592-599.
132. Berger M., Cupps T.R., Fauci A.S. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 1980, 93:55-56.
133. Gardulf A., Andersen V., Bjorkander J., et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995, 345:365-369.
134. Gardulf A., Hammarstrom L., Smith C.I. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991, 338:162-166.
135. Chapel H.M., Spickett G.P., Ericson D., et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000, 20:94-100.
136. Ochs H.D., Gupta S., Kiessling P., et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006, 26:265-273.
137. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004, 112:1-7.
138. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008, 28:779-802.
139. Moore M.L., Quinn J.M. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol 2008, 101:114-121.
140. Bonilla F.A. Pharmacokinetics of immunoglobulin administered via intravenous of subcutaneous routes. Immunol Allergy Clin North Am 2008, 28:803-819.
141. Schiff R.I. Individualizing the dose of intravenous immune serum globulin for therapy of patients with primary humoral immunodeficiency. Vox Sang 1985, 49(Suppl 1):15-24.
142. Bonagura V.R., Marchlewski R., Cox A., et al. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008, 122:210-212.
143. Gardulf A., Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006, 6:434-442.
144. Fasth A., Nystrom J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol 2008, 28:370-378.
145. Eijkhout H.W., van Der Meer J.W., Kallenberg C.G., et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001, 135:165-174.
146. Roifman C.M., Schroeder H., Berger M., et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 2003, 3:1325-1333.
147. Busse P.J., Razvi S., Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002, 109:1001-1004.
148. Imbach P., Barandun S., d'Apuzzo V., et al. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981, i:1228-1231.
149. Debre M., Bonnet M.C., Fridman W.H., et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993, 342:945-949.
150. Nimmerjahn F., Ravetch J. Fcg receptor as regulators of immune responses. Nat Rev Immunol 2008, 8:34-47.
151. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
152. Kaneko Y., Nimmerjahn F., Ravetch J. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-673.
153. Anthony R., Nimmerjahn F., Ashline D., et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 320:373-376.
154. Anthony R.M., Wermeling F., Karlsson M.C., et al. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 2009, 10:19571-19578.
155. Yu Z., Lennon V.A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999, 340:227-228.
156. Bleeker W., Teeling J., Hack C. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001, 98:3136-3142.
157. Hansen R.J., Balthasar J.P. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombycytopenia. Blood 2002, 100:2087-2093.
158. Kazatchkine M., Dietrich G., Ronda N., et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIG). Immunol Rev 1994, 139:79-107.
159. Nydegger U., Sultan Y., Kazatchkine M. The concept of anti-idiotypic regulation of selected autoimmune diseases by intravenous immunoglobulin. Clin Immunol Immunopathol 1989, 53:S72-S82.
160. Sultan Y., Kazatchkine M.D., Maisonneuve P., et al. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984, ii:765-768.
161. Berger M., Rosenkranz P., Brown C.Y. Intravenous and standard immune serum globulin preparations interfere with uptake of 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity. Clin Immunol Immunopathol 1985, 34:227-236.
162. Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol 1996, 104:21-25.
163. Dalakas M.C. Intravenous immune globulin for dermatomyositis. N Engl J Med 1994, 330:1392-1393.
164. Dalakas M.C. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 1998, 51:S37-S45.
165. Basta M., Illa I., Dalaskas M. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barré syndrome, myasthenia gravis and dermatomyositis. J Neuroimmunol 1996, 71:227-229.
166. Dalakas M.C. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997, 126:721-730.
167. Viard I., Wehrli P., Bullanim R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998, 282:490-493.
168. Negi V., Elluru S., Siberil S., et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007, 27:233-245.
169. Vassilev T., Kazatchkine M., Van Huyen J., et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use. Blood 1999, 93:3624-3631.
170. Turhan A., Jenab P., Bruhns P., et al. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood 2004, 103:2397-2400.
171. Chang J., Shi P.A., Chiang E.Y., et al. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 2008, 111:915-923.